Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22113083 | 1.00 | CHRM1 (0.49) | CHRM1SLC6A2SLC6A4LMNACYP2C9 | |
| SCHEMBL23519812 | 1.00 | CHRM1 (0.49) | CHRM1SLC6A2SLC6A4LMNACYP2C9 | |
| SCHEMBL17170586 | 0.93 | HTR3E (0.45) | CHRM1SLC6A2SLC6A4LMNACYP2C9 | |
| SCHEMBL2612617 | 0.82 | CHRM1 (0.35) | CHRM1SLC6A2SLC6A4MDM2 | |
| SCHEMBL22251721 | 0.82 | CHRM1 (0.35) | CHRM1SLC6A2SLC6A4MDM2 | |
| SCHEMBL15440767 | 0.82 | CHRM1 (0.35) | CHRM1SLC6A2SLC6A4HTR3EHTR3B | |
| SCHEMBL24467163 | 0.82 | CHRM1 (0.35) | CHRM1SLC6A2SLC6A4MDM2 | |
| SCHEMBL24301474 | 0.82 | CHRM1 (0.35) | CHRM1SLC6A2SLC6A4MDM2 | |
| SCHEMBL25518308 | 0.79 | CHRM1 (0.39) | CHRM1SLC6A2SLC6A4HTR4 | |
| SCHEMBL17953034 | 0.76 | MDM2 (0.36) | MDM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-8334297-B2 | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | RIGEL PHARMACEUTICALS INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8163771-B2 | 11 β-HSD1 modulators | EXELIXIS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | TRANSORAL PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | TRANSORAL PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | CHRM1 338/4885SLC6A2 146/4885SLC6A4 35/4885 |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | CHRM1 1021/4885SLC6A2 908/4885SLC6A4 729/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CHRM1 4885/4885SLC6A2 4861/4885SLC6A4 4877/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | CHRM1 338/4885SLC6A2 146/4885SLC6A4 35/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CHRM1 4885/4885SLC6A2 4861/4885SLC6A4 4877/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | CHRM1 1983/4885SLC6A2 2412/4885SLC6A4 1925/4885 |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | IL2, IL1B, IL1A | CHRM1 3373/4885SLC6A2 3313/4885SLC6A4 3572/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | CHRM1 328/4885SLC6A2 135/4885SLC6A4 35/4885 |
| US-20080213363-A1 | Ionized form capable of being converted into an un-ionized form; and buffer system changes the pH of saliva from an arbitrary initial pH to a predetermined final pH; sodium carbonate and sodium bicarbonate; acetic acid and sodium acetate; lozenge, chewing gum, dissolving tablet | SI, HTR3A, GALR3 | CHRM1 130/4885SLC6A2 293/4885SLC6A4 52/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CHRM1 4885/4885SLC6A2 4861/4885SLC6A4 4877/4885 |
| US-20100256210-A1 | METHODS AND COMPOSITIONS FOR DELIVERING 5-HT3 ANTAGONISTS ACROSS THE ORAL MUCOSA | SLC9A3, HTR3A, HTR3C | CHRM1 2004/4885SLC6A2 55/4885SLC6A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.